Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Irina Ermolaeva
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02666157CT.gov Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Atrial Fibrillation
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dabigatran Etexilate (this asset) | Irina Ermolaeva | Approved | BB · 67 |
| Edoxaban | National Taiwan University Hospital | P4 | A |
| Dabigatran | Pfizer | P4 | BBB |
| Rivaroxaban | VA Office of Research and Development | P4 | BBB |
| Apixaban | Regeneron Pharmaceuticals | P4 | BBB |
| Warfarin | Pfizer | P4 | BBB |
| Aspirin | Yonsei University | P4 | BBB |
| 3-(.ALPHA.-ACETONYL-P-NITROBENZYL)-4-HYDROXYCOUMARIN | University of Edinburgh | P4 | BB |
| Atecegatran Fexenetil | AstraZeneca | P2 | BB |
+32 more in the Atrial Fibrillation cohort
Other indications for Dabigatran Etexilate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Type 2 Diabetes Mellitus | — | P4 | BB · 65 |
| Chronic Kidney Disease | — | P4 | BB · 65 |
| Stroke Disorder | — | P3 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dabigatran Etexilate in Atrial Fibrillation. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dabigatran-etexilate-atrial-fibrillation
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →